AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 232 min read$MRNA

Moderna stock extends decline after leaked data on melanoma vaccine trial

Moderna (MRNA) stock fell 2% on Friday, extending a 17% drop from Thursday, after leaked data from a late-stage melanoma vaccine trial disappointed investors. The trial was conducted with Merck (MRK). Goldman Sachs (GS) raised its target to $137, while Morgan Stanley (MS) and Citi (C) maintain Neutral and Sell ratings, respectively. The stock is down from $200 despite positive Phase 3 results in August.

Original reporting
finance.yahoo.com
Published Oct 23, 2026, 1:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 1:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Moderna stock extends decline after leaked data on melanoma vaccine trial — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MRNABearishMed
01

Why it matters

The leak triggered a sell‑off, highlighting investor sensitivity to oncology trial outcomes.

02

Market read

The article provides fresh, material information on a major biotech's pipeline, creating a short‑term trading opportunity.

03

What to watch

Potential partnership revenue with Merck and long‑term pipeline diversification may cushion the hit.

Relevance 7/10Novelty 7/10Timing: pre‑market Friday

Background

Moderna's melanoma vaccine is a key growth catalyst beyond its COVID‑19 business. The trial data were leaked ahead of the official conference presentation in Madrid.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Leaked results from Moderna's late‑stage melanoma vaccine trial caused the stock to slide nearly 2% on Friday.

Expected impact

likely further downside as investors digest the disappointing figures

Evidence & confidence

Leak shows the vaccine did not meet expectations; market already reacted with a 2% drop and a $17 B market‑cap loss.

Market effects

Sector

Biotech sector may see broader risk aversion toward late‑stage oncology trials.

Regional

U.S. biotech stocks could face short‑term pressure.

Global

Limited to investors tracking cancer‑therapy pipelines.

Counterpoint

What could challenge this read

If the data are not as bad as leaked, the stock could rebound on a short‑cover rally.

Key entities

  • company
    Moderna

    Biotech firm developing personalized cancer vaccines.

Read at source← All news

StoryModerna shares tumble 17‑18% after leaked Phase 3 melanoma vaccine data

Also covered by

4 outlets

Related articles

OCT 23
$MRNALowAI 8/10

Why is Moderna stock sliding today?

Moderna's stock fell 2.3% after early release of Phase 3 trial data for its melanoma vaccine showed a 42% risk reduction, below prior expectations. Analysts reacted with mixed views, and the stock is down from its 52-week high. The broader market and sector peers are largely unaffected.

investing.com2 min
OCT 23
$MRNAMed

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Moderna (MRNA) shares fell 4% to $193.62, extending an 18% drop, after full late-stage results for its melanoma vaccine with Merck (MRK) were released. The data met expectations but fell short of high hopes, triggering a correction. Moderna's stock is more exposed due to its focus on oncology, while Merck's stock declined 0.8% to $146. Pfizer (PFE) also saw a minor decline of 0.7% to $30.22.

247wallst.com2 min
OCT 23
$MRNAHighAI 8/10

Moderna Stock Cools After Cancer Vaccine Data Leak

Moderna (MRNA) stock fell 3.9% premarket after a 17% drop yesterday. The decline followed a data leak on its cancer vaccine with Merck (MRK), which showed a 42% reduction in recurrence or death risk in phase 3 trials. The stock hit a four-year high of $254.48 on Oct. 21 and is up 587% year-to-date. Bearish bets on MRNA have increased, with a high put/call ratio.

schaeffersresearch.com1 min
OCT 23
$MRNAHigh

Moderna & Merck Cancer Vaccine Succeeds, Shares Retreat

Moderna and Merck reported that their personalized mRNA cancer vaccine, combined with Keytruda, reduced melanoma risk by 42% in a Phase 3 trial. The vaccine is tailored to individual tumor mutations. Shares of both companies fell despite positive results, with Moderna down 17% and Merck down 1.8%. The companies plan to seek U.S. approval and expect to introduce the vaccine in 2027.

tradingpedia.com3 min